Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1992 1
1993 4
1994 1
1995 2
1996 10
1997 11
1998 6
1999 12
2000 16
2001 7
2002 17
2003 34
2004 50
2005 61
2006 67
2007 46
2008 62
2009 51
2010 58
2011 60
2012 51
2013 45
2014 44
2015 45
2016 28
2017 25
2018 17
2019 16
2020 17
2021 18
2022 24
2023 25
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

830 results

Results by year

Filters applied: . Clear all
Page 1
Drug efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of postmenopausal osteoporosis: a network meta-analysis of randomized controlled trials.
Wang WY, Chen LH, Ma WJ, You RX. Wang WY, et al. Eur Rev Med Pharmacol Sci. 2023 Sep;27(17):8253-8268. doi: 10.26355/eurrev_202309_33586. Eur Rev Med Pharmacol Sci. 2023. PMID: 37750653 Free article.
OBJECTIVE: This study aims to compare the efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic acid for the treatment of women with postmenopausal osteoporosis. ...The efficacy results indicated that teriparatide was more effective …
OBJECTIVE: This study aims to compare the efficacy and safety of denosumab, teriparatide, zoledronic acid, and ibandronic a
Osteoporosis treatment: why ibandronic acid?
Rossini M, Orsolini G, Adami S, Kunnathully V, Gatti D. Rossini M, et al. Expert Opin Pharmacother. 2013 Jul;14(10):1371-81. doi: 10.1517/14656566.2013.795949. Epub 2013 May 7. Expert Opin Pharmacother. 2013. PMID: 23650954 Review.
INTRODUCTION: In this article, we have summarized the specific evidence on ibandronic acid (or ibandronate) efficacy, tolerability, and feasibility acquired from trials and clinical use. ...The safety profile of ibandronic acid treatment appears to be …
INTRODUCTION: In this article, we have summarized the specific evidence on ibandronic acid (or ibandronate) efficacy, tolerabi …
The Clinical Effectiveness of Denosumab (Prolia®) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis.
Moshi MR, Nicolopoulos K, Stringer D, Ma N, Jenal M, Vreugdenburg T. Moshi MR, et al. Calcif Tissue Int. 2023 Jun;112(6):631-646. doi: 10.1007/s00223-023-01078-z. Epub 2023 Apr 5. Calcif Tissue Int. 2023. PMID: 37016189 Review.
Ibandronate.
Dooley M, Balfour JA. Dooley M, et al. Drugs. 1999 Jan;57(1):101-8; discussion 109-10. doi: 10.2165/00003495-199957010-00011. Drugs. 1999. PMID: 9951955 Review.
Ibandronate (ibandronic acid) is a third generation bisphosphonate which inhibits hone resorption in human and animal studies. ...
Ibandronate (ibandronic acid) is a third generation bisphosphonate which inhibits hone resorption in human and animal studies. …
Oral ibandronic acid.
Gennari L. Gennari L. IDrugs. 2005 Feb;8(2):155-69. IDrugs. 2005. PMID: 15696417 Review.
Roche Holdings AG is developing an oral formulation of the bisphosphonate derivative ibandronic acid as a potential treatment for metastatic bone disease in breast cancer patients; it was filed for this indication in October 2002. ...
Roche Holdings AG is developing an oral formulation of the bisphosphonate derivative ibandronic acid as a potential treatment …
Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial.
Barrett-Lee P, Casbard A, Abraham J, Hood K, Coleman R, Simmonds P, Timmins H, Wheatley D, Grieve R, Griffiths G, Murray N. Barrett-Lee P, et al. Lancet Oncol. 2014 Jan;15(1):114-22. doi: 10.1016/S1470-2045(13)70539-4. Epub 2013 Dec 11. Lancet Oncol. 2014. PMID: 24332514 Clinical Trial.
As a result, the use of oral ibandronic acid has increased, despite the absence of comparative data. In the ZICE trial, we compared oral ibandronic acid with intravenous zoledronic acid for the treatment of metastatic breast cancer to bone. ...
As a result, the use of oral ibandronic acid has increased, despite the absence of comparative data. In the ZICE trial, we com …
Ibandronic acid: a review of its use in the treatment of bone metastases of breast cancer.
McCormack PL, Plosker GL. McCormack PL, et al. Drugs. 2006;66(5):711-28. doi: 10.2165/00003495-200666050-00011. Drugs. 2006. PMID: 16620148 Review.
Ibandronic acid (Bondronat) is a potent, new-generation, nitrogen-containing bisphosphonate, available in both intravenous and oral formulations, which effectively inhibits osteoclast-mediated bone resorption. ...Oral ibandronic acid is administered as
Ibandronic acid (Bondronat) is a potent, new-generation, nitrogen-containing bisphosphonate, available in both intravenous and
Bad Breaks.
Yalla N. Yalla N. Clin Chem. 2018 Jan;64(1):47-50. doi: 10.1373/clinchem.2017.279430. Clin Chem. 2018. PMID: 29295835 No abstract available.
Zoledronic acid is more efficient than ibandronic acid in the treatment of symptomatic bone marrow lesions of the knee.
Müller F, Appelt KA, Meier C, Suhm N. Müller F, et al. Knee Surg Sports Traumatol Arthrosc. 2020 Feb;28(2):408-417. doi: 10.1007/s00167-019-05598-w. Epub 2019 Jul 4. Knee Surg Sports Traumatol Arthrosc. 2020. PMID: 31273410 Free PMC article.
METHODS: Patient records of 34 patients with radiologically diagnosed, painful BML of the knee treated with either a bisphosphonate (zoledronic, ibandronic, or alendronic acid) or with a human monoclonal antibody (denosumab) were retrospectively evaluated. ...The hi …
METHODS: Patient records of 34 patients with radiologically diagnosed, painful BML of the knee treated with either a bisphosphonate (zoledro …
Polypharmacy in Osteoporosis Treatment.
McConnell M, Shieh A. McConnell M, et al. Clin Geriatr Med. 2022 Nov;38(4):715-726. doi: 10.1016/j.cger.2022.05.011. Epub 2022 Sep 13. Clin Geriatr Med. 2022. PMID: 36210087 Review.
Treatments for osteoporosis include antiresorptive (alendronate, risedronate, zoledronic acid, ibandronate, denosumab) and osteoanabolic (teriparatide, abaloparatide, romosozumab) agents. ...
Treatments for osteoporosis include antiresorptive (alendronate, risedronate, zoledronic acid, ibandronate, denosumab) and osteoanabo …
830 results